Metformin increases peroxisome proliferator-activated receptor γ Co-activator-1α and utrophin a expression in dystrophic skeletal muscle

Muscle and Nerve

Volumn 52, Issue 1, 2015, Pages 139-142

  Ljubicic, Vladimir ^a,b   Jasmin, Bernard J ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

AMPK; mdx mice; Metformin; PGC 1 ; Utrophin A

Indexed keywords

DYSTROPHIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RECEPTOR INTERACTING PROTEIN 140; UNCLASSIFIED DRUG; UTROPHIN; UTROPHIN A; ANTIDIABETIC AGENT; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUSCLE CELL; MUSCULAR DYSTROPHY; MYOTUBE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; SKELETAL MUSCLE; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TIME; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; METFORMIN; MICE; MICE, INBRED MDX; MUSCLE CELLS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; PPAR GAMMA; RNA, MESSENGER; TIME FACTORS; UTROPHIN;

EID: 84931563123     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.24692     Document Type: Article

References (16)

1. Ljubicic V, Burt M, Jasmin BJ. The therapeutic potential of skeletal muscle plasticity in DMD: phenotypic modifiers as pharmacologic targets. FASEB J 2014;28:548-568.
2. Ljubicic V, Jasmin BJ. AMP-activated protein kinase at the nexus of therapeutic skeletal muscle plasticity in Duchenne muscular dystrophy. Trends Mol Med 2013;19:614-624.
3. Ljubicic V, Burt M, Lunde JA, Jasmin BJ. Resveratrol induces expression of the slow, oxidative phenotype in mdx mouse muscle together with enhanced activity of the SIRT1-PGC-1α axis. Am J Physiol Cell Physiol 2014;307:C66-82.
4. Al-Rewashdy H, Ljubicic V, Lin W, Renaud JM, Jasmin BJ. Utrophin A is essential in mediating the functional adaptations of mdx mouse muscle following chronic AMPK activation. Hum Mol Genet 2015;24:1243-1255.
5. Suwa M, Egashira T, Nakano H, Sasaki H, Kumagai S. Metformin increases the PGC-1alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. J Appl Physiol (1985) 2006;101:1685-1692.
6. Kristensen JM, Treebak JT, Schjerling P, Goodyear L, Wojtaszewski JF. Two weeks of metformin treatment induces AMPK-dependent enhancement of insulin-stimulated glucose uptake in mouse soleus muscle. Am J Physiol Endocrinol Metab 2014;306:E1099-1109.
7. Casteels K, Fieuws S, van Helvoirt M, Verpoorten C, Goemans N, Coudyzer W, et al. Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit. Pediatr Diabetes 2010;11:61-69.
8. Rutter MM, Wong, BL, Rose SR, Klein DJ. Metformin improves weight gain and body mass index in Duchenne muscular dystrophy. Neuromuscul Disord 2009;19:612.
9. Weatherspoon SE, Collins J, Sucharew H, Wong BL, Rybalsky I, Rose SR, et al. Metformin reduces weight and BMI in Duchenne muscular dystrophy patients on long term glucocorticoid therapy. Neuromuscul Disord 2012;22:866.
10. Bonati U, Hafner P, Erne B, Neuhaus C, Gloor M, Bieri O, et al. Successful pilot trial of L-arginine and metformin in DMD. J Neuromuscul Dis 2014;1(suppl):S138-139.
11. Bonati U, Fischer D. L-citrulline and metformin in Duchenne's muscular dystrophy. https://clinicaltrials.gov/ct2/show/NCT01995032?term=01995032&rank=1. Accessed February 8, 2015.
12. Langone F, Cannata S, Fuoco C, Lettieri Barbato D, Testa S, Pio Nardozza A, et al. Metformin protects skeletal muscle from cardiotoxin induced degeneration. PLoS One 2014;9:e114018.
13. Ljubicic V, Miura P, Burt M, Boudreault L, Khogali S, Lunde JA, et al. Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle. Hum Mol Genet 2011;20:3478-3493.
14. Ljubicic V, Khogali S, Renaud JM, Jasmin BJ. Chronic AMPK stimulation attenuates adaptive signaling in dystrophic skeletal muscle. Am J Physiol Cell Physiol 2012;302:C110-121.
15. Huang X, Wullschleger S, Shapiro N, McGuire VA, Sakamoto K, Woods YL, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008;412:211-221.
16. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA, et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila) 2010;3:1066-176.